Tryptamine Therapeutics (ASX:TYP) entered into an exclusive biomarker development agreement with Robin Carhart-Harris, the Chair of the firm's scientific advisory board and Pedro Mediano, a professor at the Imperial College London, to develop a proprietary electroencephalogram-based platform to support the clinical development of its TRP-8803 drug candidate, according to a Thursday Australian bourse filing.
Carhart-Harris, Mediano, and the firm will work to develop a proprietary electroencephalogram-based biomarker platform, leveraging real-time cortical entropy to predict and optimize therapeutic outcomes before, during, and after intravenous administration of TRP-8803.
This could allow clinicians to identify patients that may best respond to psychedelic intervention and modulate dosing in real time to reach the optimal neuroplasticity window.
The agreement has an initial one-year term with an option to extend for another year, under which the firm will pay $100,000 per annum for the services provided. It will also grant, subject to shareholder approval, 1,000,000 options each to Carhart-Harris and Mediano, exercisable at $0.08 and expiring two years from the date of issue.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.